PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) has scheduled a conference call on June 2 at 8:30am EST to discuss results of first phase clinical studies for the investigational anesthetic agent, ABP-700, and the investigational lipid-modulating agent, MDCO-216. Summary results for ABP-700 were presented at the Dutch Society of Anesthesiology in Maastricht, Netherlands, while results for MDCO-216 were presented at the 17th International Symposium on Atherosclerosis in Amsterdam, Netherlands.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
